Tvardi Therapeutics, Inc. (TVRD)
$1.87+$0.07 (+3.76%) Today
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
https://www.tvarditherapeutics.comSEC filings for TVRD on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 5 | 30,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
13 Form 4 filings on record, the earliest from Nov 6, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Susan Ph.D. Shiff | Grant or award | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| Cynthia Smith | Grant or award | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| Sujal Shah | Grant or award | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| Wallace L. Hall Jr. | Grant or award | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| Michael S. Wyzga | Grant or award | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| Stephen Paul O'Brien - Officer | Grant or award | Employee Stock Option (right to buy) | 15,000 | $0.00 | - | |
| Avi Daniel Conn - Officer | Grant or award | Employee Stock Option (right to buy) | 45,000 | $0.00 | - | |
| John Saewook M.D. Kauh - Officer | Grant or award | Employee Stock Option (right to buy) | 45,000 | $0.00 | - | |
| Imran Nizamudin Alibhai - Officer | Grant or award | Employee Stock Option (right to buy) | 115,000 | $0.00 | - | |
 Samuel David Tweardy | Other | Common Stock | 315,658 | $0.00 | - | |
| Samuel David Tweardy | Other | Common Stock | 315,658 | $0.00 | - | |
| Michael S. Wyzga | Grant or award | Stock Option (right to buy) | 12,000 | $0.00 | - | |
| Michael S. Wyzga | Grant or award | Stock Option (right to buy) | 18,441 | - | - | |
| Christopher Posner - Officer | Open-market sale | Common Stock | 3,668 | $0.29 | $1K |
Tvardi Therapeutics, Inc. (TVRD) had 5 insider filings in the last 90 days, with the most recent on 2026-06-11. The full record for TVRD runs to 13 Form 4 filings, the earliest from 2024-11-06. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of TVRD were filed in the last 90 days.
No insider sales of TVRD were filed in the last 90 days. 1 sale is on record for this company.
This page tracks TVRD Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TVRD to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
